Bacteriophage as a potential therapy to control antibiotic-resistant *Pseudomonas aeruginosa* infection through topical application onto a full-thickness wound in a rat model

Nouran Rezk¹, Abdallah S. Abdelsattar¹,², Doaa Elzoghby¹, Mona M. Agwa³, Mohamed Abdelmoteleb⁴, Rania G. Aly⁵, Mohamed S. Fayez¹, Kareem Essam¹, Bishoy M. Zaki⁶ and Ayman El-Shibiny¹,⁷*

**Abstract**

**Background:** Antibiotic-resistant *Pseudomonas aeruginosa* (*P. aeruginosa*) is one of the most critical pathogens in wound infections, causing high mortality and morbidity in severe cases. However, bacteriophage therapy is a potential alternative to antibiotics against *P. aeruginosa*. Therefore, this study aimed to isolate a novel phage targeting *P. aeruginosa* and examine its efficacy in vitro and in vivo.

**Results:** The morphometric and genomic analyses revealed that ZCPA1 belongs to the *Siphoviridae* family and could infect 58% of the tested antibiotic-resistant *P. aeruginosa* clinical isolates. The phage ZCPA1 exhibited thermal stability at 37 °C, and then, it decreased gradually at 50 °C and 60 °C. At the same time, it dropped significantly at 70 °C, and the phage was undetectable at 80 °C. Moreover, the phage ZCPA1 exhibited no significant titer reduction at a wide range of pH values (4–10) with maximum activity at pH 7. In addition, it was stable for 45 min under UV light with one log reduction after 1 h. Also, it displayed significant lytic activity and biofilm elimination against *P. aeruginosa* by inhibiting bacterial growth in vitro in a dose-dependent pattern with a complete reduction of the bacterial growth at a multiplicity of infection (MOI) of 100. In addition, *P. aeruginosa*-infected wounds treated with phages displayed 100% wound closure with a high quality of regenerated skin compared to the untreated and gentamicin-treated groups due to the complete elimination of bacterial infection.

**Conclusion:** The phage ZCPA1 exhibited high lytic activity against MDR *P. aeruginosa* planktonic and biofilms. In addition, phage ZCPA1 showed complete wound healing in the rat model. Hence, this research demonstrates the potential of phage therapy as a promising alternative in treating MDR *P. aeruginosa*.

**Keywords:** *Pseudomonas aeruginosa*, Multi-drug resistant (MDR), Wound infection, In vivo, Bacteriophage, Biofilm, Phage characterization, Phage isolation, Immunohistochemical (IHC)

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
antimicrobial resistance. It was estimated in 2019 that about 5 million deaths were because of antibiotic-resistant bacterial infections [3]. Moreover, the World Health Organization (WHO) indicated that antimicrobial-resistant bacterial infections could kill approximately 10 million people per year by 2050 [4]. In addition, WHO has classified it as a critical pathogen that requires immediate attention to develop new antibiotics [1].

*P. aeruginosa* has a high ability to develop resistance against a wide range of antibiotics, including fluoroquinolones, aminoglycosides, β-lactams, and different disinfectants. This is because it contains intrinsic and acquired mechanisms. The intrinsic resistance of *P. aeruginosa* includes reduction of membrane permeability, overexpression of efflux pumps that pump antibiotics out of the cell, and the production of antibiotic-degrading enzymes, including AmpC β-lactamases and aminoglycoside-modifying enzymes [5, 6]. Moreover, biofilm development is considered one of the primary resistance mechanisms in *P. aeruginosa*. *P. aeruginosa* biofilms are critical in protecting bacteria from host immune responses and are up to 1000 times more resistant to antibiotics than planktonic cells [7, 8]. Multidrug-resistant (MDR) *P. aeruginosa* has been linked to nosocomial infections and outbreaks in burn and intensive care units [9–11] and is a growing cause of hospital-acquired infections [12]. *P. aeruginosa* is also considered a severe threat by the Centers for Disease Control and Prevention (CDC) because of its high mortality rate [13]. Moreover, Egypt has the highest MDR *P. aeruginosa* prevalence (75.6%) in the Middle East (MENA) region [14].

Skin is the first defense barrier against bacterial infections, and any damage to the skin allows pathogens to enter the body, resulting in sepsis and death [15]. Wounds and skin damage can be induced by chemical and physical agents and diseases like diabetes [16]. Wound infection is one of the most common nosocomial infections with a high mortality rate [17]. *P. aeruginosa* is the most frequent driver of wound infections, which colonizes the wound site followed by expansion into internal organs through the bloodstream that ends with skin necrosis and serious complications and, in severe cases, can be life-threatening [16, 18, 19]. Moreover, *P. aeruginosa* is a significant cause of delayed wound healing. A meta-analysis study showed that 78.2% of biofilms in chronic non-healing wounds were associated with poor wound healing [20, 21]. According to Ijaz et al., MDR *P. aeruginosa* was found in 58.6% of clinical samples from wounded patients [22]. Therefore, better therapeutic and prophylactic treatments for combating MDR *P. aeruginosa* wound infections are required.

Phage therapy is one of the promising alternatives to antibiotics, which utilizes naturally occurring phages that are considered part of the human microbiome [23, 24] and have high specificity towards their bacterial hosts, including biofilm-forming and antibiotic-resistant bacteria [25–27]. Many research studies have highlighted the use of phages to control biofilm-forming bacteria, including *P. aeruginosa* and demonstrated the ability of phages to eradicate the *P. aeruginosa* infections [28, 29] and biofilm-forming bacterial cells [16, 30–33]. However, previous studies have focused mainly on the treatment of cystic fibrosis caused by *P. aeruginosa* by phages in vivo [29, 34–36]. Moreover, using phage therapy against MDR *P. aeruginosa* in wound infection shows high efficacy and safety through topical and oral administrations [29, 37–39]. Hence, this study aimed to isolate and characterize a novel phage against MDR *P. aeruginosa* from Egyptian clinical isolates and study its efficacy in vitro and on infected wounds using a rat model through single and multiple doses.

**Methods**

**Bacterial characterization**

**Bacterial growth conditions**

Fifty clinical wound swabs were collected from patients in Egyptian hospitals infected with *P. aeruginosa* and given as a gift to the Center for Microbiology and Phage therapy at Zewail City for Science and Technology. First, the clinical isolates were streaked on Cetrimide agar (Oxoid, England), and *P. aeruginosa* was identified according to the standard morphology on cetrimide agar that appears fluorescent green. Then, five colonies were picked for purification and stored in Tryptic Soy Broth (TSB; Oxoid, England) containing 20% (v/v) glycerol for storage at −80 °C. Before each experiment, fresh bacterial cultures were prepared by inoculating a single colony from Cetrimide agar into 1 mL of TSB in 1.5-mL Eppendorf and incubating for 16 h at 37 °C with shaking at 200 rpm. All methods were performed following the relevant guidelines and regulations.

**Detection of *P. aeruginosa* and virulence genes using polymerase chain reaction (PCR)**

According to the manufacturer's instructions, the bacterial DNA was extracted by QIAamp DNA Mini Kit (Qiagen, Germany). Seven virulence genes were used to confirm the pathogenicity and antibiotic resistance of the bacterial strains. Briefly, the total volume of each reaction was 25 μL containing 12.5 μL of 2x master mix (Thermo Scientific), 1 μL from each stock primer, 2 μL of bacterial DNA, 0.5 μL of 50 mM MgCl2, and 8 μL of distilled water. Afterwards, the products were run through 1% (w/v) agarose gel (Sigma-Aldrich, USA) to determine the size of the PCR product. All the primer sequences, the predicted sizes, and annealing temperatures are shown in Table 1.
Antimicrobial susceptibility testing
The antibiotic profile of fifty *P. aeruginosa* isolates was investigated using the disc diffusion method [35]. The tested antibiotics were ciprofloxacin (CIP; 5 μg), gentamicin (CN; 10 μg), imipenem (IPM; 10 μg), cefepime (F; 30 μg), levofloxacin (LEV; 5 μg), amikacin (AK; 30 μg), piperacillin (PRL; 10 μg), and meropenem (MEL; 5 μg) (Oxoid, UK). The diameter of the clear zone was measured, and the results were interpreted based on the Clinical and Laboratory Standards Institute (CLSI) [43].

16S rRNA gene sequencing
A second PCR reaction was performed to identify the bacterial strain *P. aeruginosa* (Ps12), the primary host for further phage isolation and other studies using 16S rRNA gene sequencing. The PCR reaction volume was 50 μL, including 25 μL of 1x Master Mix (Thermo Scientific, USA), 5 μL of DNA sample was extracted by QIAamp DNA 93 Mini Kit (Qiagen, Germany), and 18 μL of nuclease-free water, and 1 μL of the forward primer (5′-AGAGTTTGATCCTGCTGCTGCTG-3′), 1 μL of the reverse primer (5′-TACGCTACGTAGGCGGTGCTGCTG-3′). PCR program was 94 °C for 3 min, 30 cycles at 94 °C for 30s, 55 °C for 30s, 72 °C for 1 min, and 72 °C for 10 min. In addition, 1.5 % (v/w) of the agarose gel was used in gel electrophoresis for the separation of the PCR product, and gel purification was performed of 16s rRNA gene using QIAEX II Gel Extraction Kit (Qiagen, Germany) as described in the manufacturer's protocol [41].

The 16S rRNA sequence was determined with a model 373A automated fluorescent-DNA sequencer (Applied Biosystem, USA). The nucleotide sequence of the 16s rRNA gene that was obtained was processed through Finch TV software (https://digitalworldbiology.com/FinchTV). BLASTN (Basic Local Alignment Search Tool, (http://www.ncbi.nlm.nih.gov/BLAST/Blast.cgi) against the 16S ribosomal RNA database was performed to identify the isolated strain [44]. The 16S rRNA sequence was deposited in the NCBI GenBank under accession number OL375153.

Phage isolation, purification, and propagation
More than ten sewage samples were taken from raw sewage, primary and secondary treatment stages from two different sewage treatment stations in Giza, Egypt. The samples were used for phage isolation using enrichment techniques [45, 46]. Briefly, 1mL of overnight culture from *Ps12* was added to 9 mL of sewage samples and incubated at 37 °C for 4h, 1% of chloroform was added to the mixture and centrifuged at 5000 rpm for 20 min, and the supernatant was retained. Afterwards, a spot assay was used by mixing 100 μl of exponential-phase bacterial host culture with 4 mL of soft agar (0.3% w/v agar), which was held at 55 °C, used at a suitable temperature between 45 and 50 °C, then poured into a TSA plate to create a bacterial layer. Ten microliters of each supernatant test sample was spotted on the bacterial layer, and the plates were incubated at 37 °C for 24 h. After incubation, if any clear zones or plaques were observed on the plates, then the plaques were picked using a sterile pipette tip, suspended in 100 μl of Gelatin-SM buffer [5.8 g NaCl, 2.0 g MgSO₄·7H₂O, 50 mL 1 M Tris-HCl pH 7.4, in 1-liter dH₂O], and stored at 4 °C for 4 h. Subsequently, a tenfold serial dilution of each plaque and spot assay was made on the bacterial host and repeated several times to get a single purified phage. Finally, 10 mL of the bacterial

| Primer | Sequence | Product size (bp) | Annealing temperature (°C) | References |
|--------|----------|------------------|---------------------------|------------|
| ETA    | F: GACAAGGCCTCAGATACACCAGC  
R: CGCTGCCCATTGGCCTCCAGCGCT | 396 | 60 | [40] |
| PhzI   | F: CATCAGCTTAGCAATCCC  
R: CCGAGAAACTTTTCCCCTC | 392 | 50 | [41] |
| PhzII  | F: GCAAGGTTTGTGTGGG  
R: CGCATCGAGCATGGAAC | 1,036 | 51 | [41] |
| bla-TEM| F: ATGATGTTCAACATTTCCG  
R: CTGACAGTTCAATGCTTA | 867 | 50 | [42] |
| OprL   | F: CTGCCATCACACCTTTA  
R: CTGCCCAACGGCATTTGT | 171 | 52.5 | Designed for this study |
| ExoS   | F: GCCTTGTCAGAGCTCTCAA  
R: GCTCCAGCAGTGGCTTCTT | 345 | 53.5 | Designed for this study |
| PlcH   | F: CCTGACTTTGCGTTGACT  
R: CCTGTTCCGTTCCAGTTCA | 680 | 53.5 | Designed for this study |

### Table 1 Primer set sequences for the seven virulence and resistance genes

| Primer | Sequence | Product size (bp) | Annealing temperature (°C) | References |
|--------|----------|------------------|---------------------------|------------|
| ETA    | F: GACAAGGCCTCAGATACACCAGC  
R: CGCTGCCCATTGGCCTCCAGCGCT | 396 | 60 | [40] |
| PhzI   | F: CATCAGCTTAGCAATCCC  
R: CCGAGAAACTTTTCCCCTC | 392 | 50 | [41] |
| PhzII  | F: GCAAGGTTTGTGTGGG  
R: CGCATCGAGCATGGAAC | 1,036 | 51 | [41] |
| bla-TEM| F: ATGATGTTCAACATTTCCG  
R: CTGACAGTTCAATGCTTA | 867 | 50 | [42] |
| OprL   | F: CTGCCATCACACCTTTA  
R: CTGCCCAACGGCATTTGT | 171 | 52.5 | Designed for this study |
| ExoS   | F: GCCTTGTCAGAGCTCTCAA  
R: GCTCCAGCAGTGGCTTCTT | 345 | 53.5 | Designed for this study |
| PlcH   | F: CCTGACTTTGCGTTGACT  
R: CCTGTTCCGTTCCAGTTCA | 680 | 53.5 | Designed for this study |
host culture was infected with 100 μl of a single phage to increase the number of Plaque Forming Unit (PFU)/mL, which were measured by spot assay of decimal dilutions.

**Phage characterization**

**Pulsed-field gel electrophoresis (PFGE)**

PFGE analysis was used to estimate the genome size of the isolated phage as described by Lingohr et al. [47] with slight modifications. Briefly, 100 μl of phage suspension (10⁹ PFU/mL) was mixed with 100 μl of 1.4% of plug agarose. After solidification, the plugs were immersed in lysis buffer (1 mg/mL Proteinase K [ThermoFischer Scientific, USA]); 0.2% w/v SDS [Sigma Aldrich, Gillingham, UK]; and 100 mM EDTA; 1% w/v N-Lauryl sarcosine [Sigma Aldrich, Gillingham, UK] and incubated at 55 °C for 18 h. After incubation, the plugs were washed and added to the PFGE 1.5% agarose gel and Lambda PFG Ladder (Biolabs, UK) was used. The PFGE was run for 18 h at 200 V (6 V/cm) with a 30- to 60-s switch time using a Bio-Rad CHEF DRII system (Biorad, USA). For imaging, 5 μl of ethidium bromide (Carl Roth, Germany) was added to the distilled water, washed, and analyzed under UV light at the Gel Dock imaging system (Biorad, USA).

**Host range analysis**

The lytic activity of the isolated phage against fifty clinical isolates of *P. aeruginosa* was investigated using the spot assay in triplicate as previously described [46]. The appearance of clear zones (bacterial lysis) confirmed the susceptibility of bacterial strains to the phage in the spotting area.

**Phage DNA sequencing**

Genomic DNA was extracted from the isolated phage with 10¹⁰ PFU/mL lysates. According to the manufacturer’s instructions, the DNA extraction was performed using proteinase K treatment (100 μg/mL in 10 mM EDTA pH 8), followed by resin purification using the Wizard DNA extraction kit (Promega, UK). The nucleotide sequencing was performed using the Illumina MiSeq platform. Nextera XT DNA Library Preparation Kit was used to prepare the DNA library (Illumina, Cambridge, UK). The paired-end DNA reads were evaluated for accuracy using FASTQC [48]. Moreover, low-quality bases were trimmed using PRINSEQ. Cleaned reads were de novo assembled using SPAdes [49] with multiple K-mers: 21, 33, 55, 77, and 99. Genome assembly was checked for quality using QUAST [50]. BLASTn against the NCBI Nucleotide database was used to identify closely related phages. Then, the top-matched phages were imported into MEGA-X [51] to draw a phylogenetic tree using CLUSTAL-W aligner [52] and the best Maximum likelihood fit model (GTR: general time reversible substitution model, G: Gamma distributed among sites). Open-reading frames were predicted using ORF finder. The predicted ORFs were compared against the NCBI non-redundant protein sequences (nr) database using BLASTp to identify putative coding sequences (CDSs). The predicted putative genes were compared to those predicted through PHASTER [53]. The annotated genome of the isolated phage (ZCPA1) has been deposited in the NCBI GenBank under the accession numbers OL597541-OL597590. The genetic map focusing on putative coding genes was generated using SNAPGene (GSL Biotech; available at https://www.snapgene.com; Access date: 27 July 2021).

**Physical stability of phage**

The thermal stability of the ZCPA1 with a high titer (10⁹ PFU/mL) was performed by incubating tubes containing the phage suspended in SM buffer at 37, 50, 60, 70, and 80 °C for 1 h. After incubation, the phage was enumerated through ten-fold serial dilution and spotted in triplicate by the spot test assay as previously described. Furthermore, the pH stability was investigated using various test tubes containing deionized water with a pH range (2–11) adjusted using HCl and NaOH, and incubated for 1 h [27]. Then, the phage titer was calculated by the spot test assay. In addition, the phage susceptibility against UV inactivation was determined by exposing the phage suspended in SM buffer directly to UV radiation (λ=253 nm) for 1 h. A sample was taken for phage enumeration at 10-min intervals using spot test assay in triplicate.

**Biofilm clearance assay**

The antibiofilm activity of phage was investigated against established *(Ps. 12)* biofilm. The methodology was described in previous studies [54, 55]. Briefly, the bacterial culture grown in TSB was supplemented with 0.1% glucose for biofilm enhancement, placed in a 96-well plate as six replicates and left for 48 h to form biofilm at 37 °C. After incubation, phage was added to the formed biofilm with different multiplicity of infections (MOIs): 0, 0.01, 0.1, 1, 10, and 100, and left for another 24 h. Then, the plate was washed to remove any unattached cells. A 1% crystal violet was added to the wells for staining, and 30% glacial acetic acid was used for the quantitative assay using FLUOstar® Omega Microplate Reader at OD_{540} (BMG LABTECH, Germany).

**One-step growth curve**

As previously described by Taha et al. [56], a one-step growth curve was conducted to determine the different stages of the phage replication cycle. The bacterial culture *(Ps. 12)* was grown in TSB at 10⁵ colony forming
were collected at 5 min intervals for 4 h at 37 °C. The FLUOstar® Omega plate reader was used in the multi-dose and single-dose phage with 1 × 10⁹ PFU/mL, respectively. The 4th and 5th groups were applied multi-dose and single-dose phage with 1 × 10⁹ PFU/mL, respectively. A swab for all groups was taken to calculate the bacterial count inhabiting the wound on the 3rd, 7th, 10th, and 14th days post-surgery. The gentamicin and phage (for the multi-dose group) were reapplied each time. Moreover, the wound was rated and photographed via a digital camera. The wound area was estimated using a digital caliper, and the percentage wound closure rate was calculated from the following equation [60, 61]:

\[
\text{Wound closure} \% = \left(1 - \frac{\text{Wound area on given day}}{\text{Wound area on day 0}} \right) \times 100.
\]

**Histological examination**

On the 17th day, the rats were sacrificed, followed by the removal of the tissue from the wound bed and its surrounding healthy skin to assess the skin wound healing. For histopathological investigations, the tissue was fixed in 10% formaldehyde and embedded in paraffin blocks. The skin sections were stained with hematoxylin and eosin (H&E) and examined under a light microscope (Leica, Germany). A histological examination of the whole wound area was done. The mean value of the percentage of the fibrous tissue, the granulation tissue, and the epidermal thickness was quantified using ImageJ, v1.53 (Maryland, USA). The skin appendages, hair follicles and sebaceous glands, were scored (no skin appendages in wound area = score 1, few <5/wound area = score 2, and ≥5/wound area = score 3). The skin sections were also stained with Masson trichrome staining. Image color deconvolution v1.53 (Maryland, USA) was used to quantify the percentage area of fibrosis in each specimen [62, 63].

**Immunohistochemical (IHC) staining and interpretation**

IHC of all sections was done using the Avidin-Biotin-Peroxidase method [64]. CD45 (ready to use primary antibody, mouse anti-human, monoclonal antibody, P0042; Leica Biosystems, USA) and α-SMA (ready to use primary antibody, mouse anti-human, monoclonal antibody, P0943; Leica Biosystems, USA) were used to stain the lymphocytes, blood vessels, and myofibroblasts...
respectively. The antibodies were added to each section using the Bond-Max fully automated immunostainer (Leica Biosystems, USA). Positive control for each primary antibody using tonsil and leiomyoma was added in each run. Negative control omitting the primary antibody was also added in each run. The IHC quantification of CD45 and α-SMA was performed on each slide using the quantitative-image analysis (Leica microsystems, Switzerland).

Statistical analysis
All experiments were conducted in triplicates, and the results were illustrated in the form of mean ± standard deviation (SD). In this study, GraphPad Prism v5 software was used to generate graphs and perform all statistical analyses. Both Student’s t-test (two-tailed) and ANOVA tests were used during the work to evaluate the significance \( p < 0.05 \).

Results

Bacterial characterization
Antibiotic susceptibility is classified into sensitive, intermediate, and resistant (Additional file 1: Table S1). The majority of the bacterial strains showed a high resistance pattern to fluoroquinolones (FQs), with 65% of levofloxacin resistance and 59% of ciprofloxacin resistance. These findings indicated that \( \text{P. aeruginosa} \) was more resistant to levofloxacin than ciprofloxacin. Moreover, the \( \text{P. aeruginosa} \) isolates exhibited high resistance to beta-lactams, including 67% resistance to meropenem. Gentamicin demonstrated a high resistance pattern at 63%. Accordingly, 29 of the tested \( \text{P. aeruginosa} \) isolates were MDR bacteria.

Moreover, seven virulence and antibiotic-resistance genes (\( \text{Exo A, Exo S, Phz I and II, bla-TEM, OprL and plcH} \)) have been identified in the ten resistant \( \text{P. aeruginosa} \) isolates tested using PCR. Furthermore, using BLASTn, the 16S rRNA sequence of \( \text{P.s} \) 12 was found to be 99% identical to \( \text{P. aeruginosa} \) strain B19 16S ribosomal RNA gene, the partial sequence with GenBank Acc. No. MZ425417.1.

Phage characterization

The ZCPA1 phage morphology
According to the morphology of the phage, it belongs to the \( \text{Siphoviridae} \) family. The phage consists of an icosahedral head and a long noncontractile flexible tail. The phage head-to-tail length ratio was similarly typical of the \( \text{Siphoviridae} \) family, with a 66.80-nm width of icosahedral head and 188.54 nm long tail (Fig. 1).

Host range analysis
The lytic activity of the phage ZCPA1 against different resistant bacterial strains was evaluated. The ZCPA1 exhibited a broad host range with lytic activity against 58% of the tested \( \text{P. aeruginosa} \) clinical isolates (Table 2).

Physical stability of the phage
To use ZCPA1 in therapy, phage stability was examined against various environmental conditions, including heat, pH, and UV. The ZCPA1 exhibited thermal stability at 37 °C with \( 10^9 \) PFU/ mL, then decreased gradually to \( 10^8 \) PFU/mL at 50 °C and 60 °C. At the same time, it dropped significantly to \( 10^6 \) PFU/mL at 70 °C, and the phage was undetectable at 80 °C (Fig. 2A). Moreover, phage ZCPA1 exhibited no significant titer reduction at a wide range of pH values (4–10) with maximum activity at pH 7, and the phage performance was changed after exposure to extreme pH conditions as its infectivity was significantly inactive at pH 2, 3, and 11 (Fig. 2B). In addition, the phage showed resistance to UV inactivation for 45 min under UV light with one log reduction after 1 hour (Fig. 2C).

The phage genome
The genome of phage ZCPA1 has been sequenced and deposited in the GenBank database (GenBank Acc. No. OL597541:OL597590). Phage ZCPA1 contains a double-stranded DNA genome of 46 kbp, which also agreed with the PFGE results. The phage ZCPA1 has an overall G + C content of 64.04%. Moreover, BLASTn analysis
confirmed that ZCPA1 is a member of the *Siphoviridae* family, in the order of *Caudovirales*. Assembly parameters were as follows: contigs# 476, N50 1648, L50 8, N’s per 100 kb 0. BLASTn alignment and phylogenetic tree showed that *Pseudomonas* phage vB_PaeS_PcyII-40_PfiIL40a isolate genome, chromosome (GenBank Acc. No. LT608331.1), was closely related to the genome of ZCPA1 (Fig. 3). The annotated genes were manually curated and listed in Additional file 1: Table S2. The open reading frames (ORFs) prediction applying the standard genetic code identified ninety putative protein-coding genes. The functional genes of phage ZCPA1 are shown in the genetic map (Additional file 1: Figure S1). Among these, forty predicted proteins have assigned functions, involving cell lysis proteins, DNA replication/transcription/reap structural proteins, and DNA packaging proteins. ZCPA1 has fifty ORFs on the leading strand and forty ORFs on the complementary strand.

### In vitro characterization of phage ZCPA1

A one-step growth curve determined the replication cycle of the phage ZCPA1 (Fig. 4A). The IC refers to the phage infective centers, indicating the number of free virions released from the bacterial cells without the addition of chloroform, while PFU indicates the number of virions inside and outside the bacterial cell due to chloroform addition. The latent phage period was estimated to be about 90 min, in which the phage virions were naturally released from the bacterial host. The eclipse period of the phage was about 45 min, which indicates the required time for viral particles to be synthesized and assembled since the bacterial lysis was aided by chloroform addition. The burst size was calculated at about 68 virions per single bacterium.

The lytic activity of phage against *Ps* 12 was tested at different MOIs (0.1, 1, 10, 100). During the first 3h, the bacterial turbidities at OD$_{600}$ were 0.295 ±0.02 for bacterial control, 0.264 ±0.03 for MOI 0.1, 0.242 ±0.01 for MOI 1, 0.056 ±0.005 for MOI 10, and around 0 for MOI 100. However, after 4 h-incubation, the media turbidity changed to OD$_{600}$ values of 0.72, 0.70, 0.493, 0.09, and around 0 for the control bacteria (bacteria without phage treatment) and the bacteria treated with phage at various MOIs, in the same order as described above. (Fig. 4B). As a result, the optimum MOI of the phage ZCPA1 is 10.

### Biofilm clearance assay

Besides, the phage ZCPA1 exhibited a high level of reduction in the *Ps* 12 biofilm biomass, starting from low MOIs of 0.1 to high MOIs of 100. At OD$_{540}$, the established biofilm biomass by *Ps* 12 was 1.67, 1.47, 0.23, 0.11, 0.09, and 0.12 for the -ve control and phage with MOI of 0.01, 0.1, 1, 10, and 100, respectively (Fig. 5).

### In vivo wound healing

**Photodocumentary analysis and wound healing percentage**

The wound closure percentage, bacterial count, and histopathological analysis throughout 17 days indicate that the phage ZCPA1 is a promising antibacterial agent against the MDR *P. aeruginosa* with high-quality wound healing in a full-thickness wound infection in a rat model. Figure 6A and B display the percentage of wound closure, which is critical for the successful repair of wound tissues. By day 17, both phage-treated groups showed prompt epithelialization of the wound area, evidenced by a higher percentage of wound closure of 99.84% and 99.93% for the groups in which phage was applied in single and multiple doses, respectively. On the other hand, the negative control group that applied sterile gauze showed a lower percentage of wound closure (69.66%). In addition, the gentamicin-treated group exhibited expansion and enlargement of the wound area, resulting in non-healing wounds with purulence and foul odor. The bacterial count

---

**Table 2** The lytic activity of phage ZCPA1 against 50 clinical isolates of *P. aeruginosa* (*Ps* 1 to *Ps* 50)

| Bacterial strain | ZCPA1 | Bacterial strain | ZCPA1 | Bacterial strain | ZCPA1 | Bacterial Strain | ZCPA1 | Bacterial strain | ZCPA1 |
|------------------|-------|------------------|-------|------------------|-------|------------------|-------|------------------|-------|
| *Ps* 1           | +     | *Ps* 11          | –     | *Ps* 21          | +     | *Ps* 31          | +     | *Ps* 41          | –     |
| *Ps* 2           | –     | *Ps* 12          | +     | *Ps* 22          | +     | *Ps* 32          | +     | *Ps* 42          | –     |
| *Ps* 3           | +     | *Ps* 13          | +     | *Ps* 23          | +     | *Ps* 33          | +     | *Ps* 43          | –     |
| *Ps* 4           | –     | *Ps* 14          | –     | *Ps* 24          | +     | *Ps* 34          | +     | *Ps* 44          | –     |
| *Ps* 5           | –     | *Ps* 15          | +     | *Ps* 25          | +     | *Ps* 35          | –     | *Ps* 45          | –     |
| *Ps* 6           | –     | *Ps* 16          | +     | *Ps* 26          | +     | *Ps* 36          | +     | *Ps* 46          | –     |
| *Ps* 7           | –     | *Ps* 17          | +     | *Ps* 27          | +     | *Ps* 37          | +     | *Ps* 47          | –     |
| *Ps* 8           | –     | *Ps* 18          | +     | *Ps* 28          | +     | *Ps* 38          | +     | *Ps* 48          | –     |
| *Ps* 9           | –     | *Ps* 19          | +     | *Ps* 29          | +     | *Ps* 39          | +     | *Ps* 49          | –     |
| *Ps* 10          | –     | *Ps* 20          | +     | *Ps* 30          | +     | *Ps* 40          | –     | *Ps* 50          | –     |

+ indicates lysis, and – indicates no lysis
Fig. 2 The physical stability of the phage ZCPA1. **A** Phage viability at different temperatures, **B** phage viability at different pH values, and **C** phage viability under UV light ($\lambda = 253$ nm). *ns* stands for no significance, *P* < 0.05, **P** < 0.01, and ***P** < 0.001.

Fig. 3 Phylogenetic relationships between phage ZCPA1 and BLASTn top-matched phages. The closely related phage is *Pseudomonas* phage vB_PaeS_PcyII-40_PfII40a isolate PfII40A reads genome assembly (GenBank Acc. No. LT608331.1)
of the wounds for all the groups was investigated throughout the 14 days. According to Fig. 6C, the detection limit was $10^2$ CFU/mL. The single phage dose showed a 4 log$_{10}$ reduction, while multiple phage doses exhibited more than 4 log$_{10}$ reductions in the total bacterial count. In contrast, the gentamicin-treated wound showed a 2 log$_{10}$ reduction compared to the positive control.

**Histopathological analysis of wound healing**

Figure 7 shows skin specimen from the positive control group (group 1) exhibited epidermal re-epithelialization (green arrow) $52.3\pm0.4 \mu m$ with the regeneration of the appendages $\geq 5$/wound area (score 3) (evidenced by H&E staining $\times 100$). The dermis was formed predominantly of collagen fibers and fibrous tissue $95.3\pm3.2\%$ (remodeling phase) (highlighted by the Masson's trichrome stain $\times 100$). The granulation tissue was minimal and formed of few newly formed blood vessels $6\pm2.1$/HPF, few myofibroblasts $7\pm1.2$/HPF (highlighted by the immunohistochemistry for $\alpha$-SMA, $\times 400$), and few lymphocytes $6\pm2.0$/HPF (highlighted by the immunohistochemistry for CD-45, $\times 400$). Skin specimen from the negative...
Fig. 6 The nontreated and noninfected wound (positive control; group 1), nontreated infected wound (negative control; group 2), infected wound treated with gentamicin antibiotic (group 3), infected wound treated with multiple phage doses (group 4), and the infected wound treated with single phage dose (group 5) from day zero till day 17. A Morphometric analysis of full-thickness excision infected wounds in rats by millimeter (mm) at a fixed focal distance. B Percentage of wound closure throughout the 17 days. C Enumeration of bacteria in the wound for the four groups throughout 14 days.

Fig. 7 Representative histopathological images of wound tissues on day 17. A Hematoxylin and eosin (H&E) staining, ×100, Masson Trichrome stain, ×100, and B IHC by using α-SMA and CD-45, ×400 (skin adnexa; white arrow, skin ulceration; black arrow, epidermis; green arrow, blood vessels; red arrow, myofibroblasts; blue arrow, lymphocytes; yellow arrow).
control group (group 2) showed extensive epidermal ulceration and crust formation 34±3.2, lacking skin appendages (H&E staining ×100). The dermis showed an excessive number of inflammatory cells (inflammatory phase) and a minimal amount of fibrous tissue (highlighted by the Masson's trichrome stain ×100) 2.1±0.3%. The granulation tissue was formed of newly formed blood vessels 25±2/HPF, myofibroblasts 20.4±2.5/HPF (highlighted by the immunohistochemistry for α-SMA, ×400), and an increased number of lymphocytes 78±4.2/HPF (highlighted by the immunohistochemistry for CD-45, ×400). Skin specimen from gentamicin treated group (group 3) showed epidermis ulceration, lacking skin appendages (evidenced by H&E staining ×100). The dermis demonstrated the inflammatory healing phase formed of few amounts of fibrous tissue (highlighted by the Masson's trichrome stain ×100) 7.8±3.5%, an increased amount of granulation tissue formed of newly formed blood vessels 40±1.6/HPF, myofibroblasts 32±6.3/HPF (highlighted by the immunohistochemistry for α-SMA, ×400), and the number of lymphocytes 40±3.7/HPF (highlighted by the immunohistochemistry for CD-45, ×400). Skin specimen from multiple phase doses treatment (group 4) showed epidermal re-epithelialization of thick epidermis 61.2±1.2 μm with the regeneration of the skin appendages ≥5/wound area (score 3), (evidenced by H&E staining ×100). The dermis demonstrated the remodeling phase of wound healing formed mainly of collagen fibers 99±0.6% (highlighted by the Masson's trichrome stain ×100) and a minimal amount of granulation tissue formed of newly formed blood vessels 2±0.4/HPF, myofibroblasts 1.4±0.3/HPF (highlighted by the immunohistochemistry for α-SMA, ×400), and lymphocytes 3±0.3/HPF (highlighted by the immunohistochemistry for CD-45, ×400).

Skin specimen from single phase dose treatment (group 5) displayed the epidermal re-epithelialization of thick epidermis 58±1.8 μm with the regeneration of the skin appendages ≥5/wound area (score 3) (evidenced by H&E staining ×100). The dermis was in the remodeling phase of wound healing, formed mainly of collagen fibers (highlighted by the Masson's trichrome stain ×100) 97.3±2.3%, and a minimal amount of granulation tissue formed of newly formed blood vessels, 4±1/HPF, myofibroblasts 3±1.4/HPF, (highlighted by the immunohistochemistry for α-SMA, ×400), and lymphocytes 5±2.2/HPF (highlighted by the immunohistochemistry for CD-45, ×400).

**Discussion**

Due to the misuse of antibiotics in clinical therapy, bacteria have evolved resistance against most commercial antibiotics. Many studies have demonstrated that phages are one of the most potent weapons for eradicating *P. aeruginosa* biofilms and planktonic cells due to their natural abundance, specificity, and safety [65].

This study isolated 50 clinical isolates of *P. aeruginosa* from Egyptian hospitalized patients and screened for antibiotic sensitivity. Their antibiotic profile indicated that the isolated *P. aeruginosa* were more resistant to levofloxacin than ciprofloxacin, which agreed with Zhao et al. [66]. FQs are the most commonly used antibiotics against *P. aeruginosa* infections; however, *P. aeruginosa* acquires resistance to the FQs through overexpression of efflux pumps and point mutations in target site genes [67]. Moreover, the tested *P. aeruginosa* isolates exhibited high resistance to β-lactams because of β-lactamase production, especially the AmpC β-lactamase, efflux pump expression, permeability changes, and changes in the target site [5, 68]. Besides, the *P. aeruginosa* isolates revealed high resistance to gentamicin, which agreed with a previous study that showed high aminoglycoside resistance among MDR and extensively drug-resistant (XDR) *P. aeruginosa* clinical isolates in Egypt [69]. Another study showed that the primary mechanism of resistance against aminoglycoside is methyltransferases responsible for changing the drug-binding sites [70]. Accordingly, 29 of the tested *P. aeruginosa* isolates in this study were MDR bacteria [71]. Seven virulence and antibiotic resistance of the tested *P. aeruginosa* isolates were confirmed using PCR, involving *Exo A*, *Exo S*, *Phz I and II*, *bla-TEM*, *OprL*, and *plcH*. *Exo A* gene is exotoxin A, which is responsible for local tissue damage and invasion of infection [72]. At the same time, the production of *Exo S* was recently linked to chronic infections as it causes cell necrosis, inhibition of DNA synthesis, and endocytosis [73]. In addition, *Phz I* and *Phz II* are required for pyocyanin production, which destroys the host cells and is essential for biofilm formation [74].

Moreover, the *Bla-TEM* gene indicates β-lactam resistance [75]. *OprL* is an essential component of the outer membrane of the bacterial cell, which maintains its integrity and is considered a marker for identifying *P. aeruginosa*-associated infections [76]. In addition, *Plec* encodes a hemolytic toxin that destroys cell membranes and phospholipids [77]. According to the antibiotic profile and virulence genes, *Ps* 12 was chosen as a multi-drug resistant bacterial host for phage isolation and further studies. The phage ZCPA1 was isolated from raw sewage water sampled from Giza, Egypt, and both morphological analysis by TEM and genome sequencing confirmed that it belongs to the *Siphoviridae* family. The host range, physical stability against harsh environmental conditions, and lytic activity against planktonic and biofilm biomass of potential therapeutic phages are critical for ensuring their efficacy in being a good therapeutic
agent. The potential phage for therapy must withstand a wide range of pH and temperature conditions in clinical and environmental applications [78]. The phage ZCPA1 exhibited a broad host range, which could infect 58% of the tested resistant P. aeruginosa clinical strains (n = 50). In addition, it showed good stability at a wide range of temperatures (37, 50, 60, and 70 °C) and a wide range of pH values (4–10). According to De Plano et al., the capsid structure of phages has been proposed for their resistance to harsh physical and chemical conditions, including pH and heat [79]. Besides, the reduction in phage titer at harsh pH conditions is due to the aggregation of viral particles, as shown by Langlet et al. [80]. Also, the phage ZCPA1 showed stability against UV light, which could be due to its linear double-stranded DNA. The type and organization of the phage genome can significantly affect the resistance of phage to UV inactivation. For example, phages with circular single-stranded DNA are more sensitive than those with linear single-stranded RNA. Those with linear double-stranded DNA exhibited the highest photoreactivation following UV exposure [81, 82].

Regarding the replication dynamics of phage ZCPA1, the one-step curve indicated that the latent period was about 90 min that could be relatively long compared to Pseudomonas phage DRL-P1 in a study by Sharma et al. [83]. Therefore, it could be explained that bacterial density is inversely proportional to the latent phase period since the low bacterial concentration led to a longer phase latent period [84]. In this study, the ability of the phage to reduce the bacterial growth of Ps 12 was tested by a time-killing curve at different MOIs (0.1, 1, 10, 100). Based on the obtained results, the MOI 0.1 exhibited a negligible reduction in bacterial growth (p > 0.05), while starting from MOI 1, there was a significant bacterial reduction (p < 0.01). The highest level of bacterial reduction was observed at MOIs 10 and 100 (p < 0.001).

P. aeruginosa biofilm formation is a critical factor in pathogenicity and antimicrobial resistance [83]. It is also considered critical in delaying wound healing and leading to chronic wound infections [85]. As a result, the lytic activity of the phage ZCPA1 was evaluated against the established biofilm by Ps 12. Accordingly, at MOI 0.01, there was an insignificant reduction in the bacterial biofilm biomass (p > 0.05). However, at MOIs 0.1, 1, 10, and 100, there was about a 95% reduction in bacterial biofilm biomass (p < 0.001). According to these data, the phage ZCPA1 can significantly eradicate P. aeruginosa planktonic cells and biofilms. These findings agreed with previous studies [25]. According to Adnan et al., after 6-h treatment with MA-1 phage, it exhibited a significant (99.9%) reduction of 74-h-old biofilms compared to control [86]. In another study, the researchers isolated the AZ1 phage and tested its anti-biofilm activity, and the results showed about 99.9% reduction of 48-h-old biofilm biomass compared to the control [87]. As a result, the phages could have significant anti-biofilm activity. The ability of the phage to break down the biofilm structure is due to encoding a wide range of enzymes, including depolymerases and lysins. The depolymerases can specifically bind and degrade the exopolysaccharide of the host bacterial cells, disturbing the biofilm to facilitate the phage penetration to the bacterial cells. In addition, lysins are hydrolyses encoded in the late stage of the lytic cycle of phage infection. They break down the peptidoglycans in the bacterial cell wall, releasing phage progenies from host cells and causing lysis and death [26].

In this study, the therapeutic efficiency of phage ZCPA1 was assessed on rats to treat full-thickness wounds infected with Ps 12. The wound closure percentage, bacterial count, and histopathological analysis throughout 17 days indicate that the phage ZCPA1 could be a promising antibacterial agent against the MDR P. aeruginosa with high-quality wound healing in a full-thickness wound infection in a rat model. Multiple research studies conducted in vivo experiments to study phages’ therapeutic effect and safety against a wide range of MDR bacteria. They exhibited significant results for killing the bacteria with minimal side effects [88–90]. Moreover, the efficacy of phage therapy against MDR P. aeruginosa in animal models was investigated. The researchers showed that phage could lead to a complete reduction of the bacterial count, inhibition of biofilm formation, and improvement of wound healing [25, 28, 34–37, 88, 91, 92].

Consequently, the influence of a topical application of phage ZCPA1, administered as single or multiple doses versus gentamicin antibiotic, was investigated in a rat model with P. aeruginosa-infected full-thickness excision wound. Skin regeneration, including restoring tissue integrity and function, is the most challenging aspect of wound treatment, as shown by Tottoli et al. [93]. However, the results in this study were promising as photo documentation and bacterial count demonstrated that the phage administration, either single-dose or multidose, resulted in 100% bacterial eradication and wound closure. Furthermore, the equivalent results between single-dose and multi-dose phage treatment underlined its self-replicating nature in the presence of susceptible microorganisms, a highly desired characteristic for any antibacterial drug [94].

Furthermore, re-epithelization is critical to successful wound healing [95]. According to the results of our histopathological analysis, both the single-dose and multiple-dose phage-treated rats showed epidermal re-epithelialization of the thick epidermis with the regeneration of the skin appendage similar to the uninfected-wound rats (positive control). In contrast, the
gentamicin-treated rats showed epidermis ulceration, lacked skin appendages, and the infected rats without treatment (negative control) exhibited extensive epidermal ulceration and crust formation without skin appendages. According to Yousefpour et al., exposure of the *P. aeruginosa* to the sub-MIC dose of gentamicin showed increased bacterial virulence due to the antibiotic stress [96]. As the infected wound showed a healing delay in the infected group without treatment and the gentamicin-treated group, bacterial resistance can develop significant wound delay with serious complications. Moreover, we recommend extending this experiment to evaluate the efficacy of antibiotics to which the bacterial strain is sensitive, for example, imipenem, as the positive control. In addition, we can study the synergistic effect of phage when combined with two types of antibiotics, one to which the bacterial strain is sensitive and another is resistant as recent publications are recommending the combination therapy [97, 98].

The results of this study have shown the potential of phage for controlling full-thickness excision wounds caused by *P. aeruginosa*. It is recommended for further studies to study the antibiofilm ability of the phage against established biofilm by *P. aeruginosa* on the wound-infected rat model.

### Conclusions

The emergence of antibiotic resistance has led researchers to look for a safe and effective alternative to antibiotics. Phage therapy has exhibited the potential to control the MDR bacteria, such as *P. aeruginosa*. In this study, a novel phage ZCPA1 was isolated and characterized in vitro against MDR *P. aeruginosa*. ZCPA1 is a member of the *Siphoviridae* family, with a wide host range and high temperature, pH, and UV stability. Moreover, it has high lytic activity against MDR *P. aeruginosa* in planktonic and biofilms. The therapeutic efficacy of ZCPA1 was investigated in a full-thickness wound infected with *P. aeruginosa* in a rat model. *P. aeruginosa* inoculated wounds treated with phage showed 100% wound closure, high-quality regeneration, and complete bacterial infection elimination. Therefore, all these properties make phage ZCPA1 a promising therapeutic agent against *P. aeruginosa* skin wound infections. However, more research is required on the phage formulations to be used topically on wound infections and tested in clinical trials.

### Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s43141-022-00409-1.

**Additional file 1:** Table S1. Antimicrobial susceptibility test for *P. aeruginosa* isolates over eight different antibiotics. Table S2. Genome annotation of the ZCPA1 genome. Figure S1. The genetic map of the phage ZCPA1.

**Acknowledgements**

The authors would like to thank Dr. Mohamed Elhadidy for his help in the clinical sample collection and support. In addition, we would like to thank Fatma Abdelrahman and Reham Atteya for extracting phage DNA and sequencing.

**Authors’ contributions**

Conceptualization, A.E.-S. and N.R.; methodology, N.R., D.M., M.M.A., R.G.A., B.M.Z, M.S.F, and K.E.; software, A.S.A. and M.A.; validation, A.E.-S. and N.R.; writing—original draft preparation, N.R., A.S.A., DM, M.M.A., R.G.A., and A.E.-S.; writing—review and editing, N.R., A.E.S., and B.M.Z.; supervision, A.E.-S.; project administration, A.E.-S.; funding acquisition, A.E.-S. All authors have read and agreed to the published version of the manuscript.

**Funding**

This research was funded by the Academy of Scientific Research and Technology (ASRT), Genetic call (51/2020), and Zewail City of Science and Technology internal grant no. ZC 019-2019.

**Availability of data and materials**

The dataset presented in this study can be found in NCBI GenBank. The 16s rRNA sequence was deposited under the accession number OL375153. In addition, the annotated genome sequence of the phage ZCPA1 was deposited under the accession numbers OLS97541-OL597590.

**Declarations**

**Ethics approval and consent to participate**

All methods were carried out according to relevant guidelines and regulations and approved by the Institutional Review Board of Animal Care Committee of the Alexandria University (ALEXU-IACUC) (AU-IACUC-14/2100601-3-6 and 1 June 2021). Furthermore, this study is reported according to ARRIVE guidelines (https://arriveguidelines.org).

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare no competing interests.

**Author details**

1. Center for Microbiology and Phage Therapy, Zewail City of Science and Technology, Giza 12578, Egypt. 2. Center for X-ray and Determination of Structure of Matter, Zewail City of Science and Technology, Giza 12578, Egypt. 3. Department of Chemistry of Natural and Microbial Products, National Research Centre, Dokki, Giza 12622, Egypt. 4. Department of Botany, Faculty of Science, Mansoura University, Mansoura 35516, Egypt. 5. Department of Surgical Pathology, Faculty of Medicine, Alexandria University, Alexandria 21131, Egypt. 6. Microbiology and Immunology Department, Faculty of Pharmacy, October University for Modern Sciences and Arts (MSA), Giza 11787, Egypt. 7. Faculty of Environmental Agricultural Sciences, Arish University, Arish 45511, Egypt.

Received: 15 May 2022 Accepted: 24 August 2022

Published online: 12 September 2022

**References**

1. Shrivastava SR, Shrivastava PS, Ramasamy J (2018) World Health Organization releases global priority list of antibiotic-resistant bacteria to guide
research, discovery, and development of new antibiotics. JMS - J Med Soc 32(1):76–77. https://doi.org/10.4103/jms.jms_25_17

2. Reynolds D, Kollef M (2021) The epidemiology and pathogenesis and treatment of Pseudomonas aeruginosa infections: an update. Drugs 81(18):2117–2131. https://doi.org/10.1007/s40265-021-01635-6

3. Murray CJ et al. (2022) Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet 6736(21). https://doi.org/10.1016/s0140-6736(21)02724-0

4. World Health Organization, New report calls for urgent action to avert antimicrobial resistance crisis, Joint News Release, 2019. https://www.who.int/ news-room/ detail/29-04-2019-new-report-calls-for-urgent-action-to-avert-antimicrobial-resistance-crisis

5. Torrens G et al (2019) Regulation of AmpC-driven β-lactam resistance in Pseudomomas aeruginosa: different pathways, different signaling. mSystems 4(6):e00524-19. https://doi.org/10.1128/mSystems.00524-19

6. Langendonk RF, Nell DR, Fothergill JL (2021) The building blocks of antimicrobial resistance in Pseudomonas aeruginosa: implications for current resistance-breaking therapies. Front Cell Infect Microbiol 11:1–22. https://doi.org/10.3389/fcimb.2021.665759

7. Breidenstein EBM, de la Fuente-Núñez C, Hancock REW (2011) Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol 19(10):419–446. https://doi.org/10.1016/j.tim.2011.04.005

8. Thi MT, Wibowo D, Rehm BHA (2020) Pseudomonas aeruginosa biofilms. Int J Mol Sci 21(22):1–25. https://doi.org/10.3390/ijms21228671

9. Hsuhe PR, Teng LI, Yang PC, Chen YC, Ho SW, Luh KT (1998) Persistence of a multidrug-resistant Pseudomonas aeruginosa clone in an intensive care burn unit. J Clin Microbiol 36(5):1347–1351. https://doi.org/10.1128/JCM.36.5.1347-1351.1998

10. Panghal M, Singh K, Kadyan S, Chaudary U, Yadav JP (2015) The analysis of distribution of multidrug resistant pseudomonas and bacillus species from burn patients and burn ward environment. Burns 41(4):812–819. https://doi.org/10.1016/j.bums.2014.10.014

11. Willmann M et al (2014) Analysis of a long-term outbreak of XDR Pseudomonas aeruginosa: a molecular epidemiological study. J Antimicrob Chemother 70(5):1322–1330. https://doi.org/10.1093/jac/dku346

12. del Barro-Toñoño E, López-Causapié C, Oliver A (2020) Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired β-lactamases: 2020 update. Int J Antimicrobial Agents 56(6):106196. https://doi.org/10.1016/j.ijantimicag.2020.106196

13. US Department of Health and Human Services and CDC. Antibiotic resistance threats in the United States, Centers for Disease Control and Prevention, pp. 1–113, 2019, [Online]. Available: https://www.cdc.gov/drugresistance/biggest_threats.html

14. Al-Orphaly M et al (2021) Epidemiology of multidrug-resistant Pseudomonas aeruginosa in the Middle East and North Africa, Region. Msphere 6(3). https://doi.org/10.1128/msphere.00202-21

15. Ávila MM, Sabra S, Atwar NA, Daidsher HA, Lathis RM, Elmotasem H (2022) Potential of frankincense essential oil-loaded whey protein nanoparticles embedded in frankincense resin as a wound healing film based on green technology. J Drug Delivery Sci Technol:103291. https://doi.org/10.1016/j.jddts.2022.103291

16. Moghadam MT, Khoshbayan A, Chegini Z, Jazireian P, Shariati A (2020) Bacteriophage therapy against Pseudomonas aeruginosa biofilms: a review. Ann Clin Microbiol Antimicrob 19(1):1–17. https://doi.org/10.1186/s12941-020-00389-5

17. Abdelrahman F et al (2022) Isolation, characterization, and genomic analysis of three novel E. coli bacteriophages that effectively infect E. coli O157:H7. Microorganisms 10(3):589. https://doi.org/10.3390/microorganisms10030589

18. Heo YJ, Lee YR, Jung HH, Lee J, Ko GP, Cho YH (2009) Antibacterial efficacy of phages against Pseudomonas aeruginosa infections in mice and Drosophila melanogaster. Antimicrob Agents Chemother 53(6):2469–2474. https://doi.org/10.1128/AAC.01646-08

19. Silva C et al (2021) The history and applications of phage therapy in Pseudomonas aeruginosa. Microbes Res 13 (1):14–37. https://doi.org/10.3390/microbiolres13010002

20. Gutierrez D, Vandenheuvel D, Martinez B, Rodriguez A, Lavigne R, Garcia P (2015) Two phages, phiPLA-RODI and phiPLA-CLC, lyse mono- and dual-species staphylococcal biofilms. Appl Environ Microbiol 81(10):3336–3348. https://doi.org/10.1128/AEM.03560-14

21. Chen B, Abedon S (2014) Bacteriophages and their enzymes in biofilm control. Curr Pharm Des 21(1):85–99. https://doi.org/10.2174/138161282066614095112311

22. Oliveira VC et al (2020) Identification and characterization of new bacteriophages to control multidrug-resistant Pseudomonas aeruginosa biofilm on endotracheal tubes. Front Microbiol 11:2401. https://doi.org/10.3389/fmicb.2020.682255

23. Sharma S et al (2021) Isolation and characterization of a lytic bacteriophage against Pseudomonas aeruginosa. Sci Rep 11(1):19393. https://doi.org/10.1038/s41598-021-98457-z

24. Forti F et al (2018) Design of a broad-range bacteriophage cocktail that reduces pseudomonas aeruginosa biofilms and treats acute infections in two animal models. Antimicrob Agents Chemother 62(6). https://doi.org/10.1128/AAC.02573-17

25. Waters EM et al (2017) Phage therapy is highly effective against chronic lung infections with Pseudomonas aeruginosa. Thorax 72(7):666–667. https://doi.org/10.1136/thoraxjnl-2016-209265

26. Yang X, Haque A, Matsuzaki S, Matsumoto T, Nakamura S (2017) The efficacy of phage therapy in a murine model of Pseudomonas aeruginosa pneumonia and sepsis. Front Microbiol 12(July):1–9. https://doi.org/10.3389/fmicb.2021.682255

27. Holguin AV et al (2015) Phage FpAn70, a putative temperate phage, controls pseudomonas aeruginosa in planktonic, biofilm and burn mouse model assays. Viruses 7(8):4602–4623. https://doi.org/10.3390/v7082835

28. McVay CS, Velasquez M, Frickel JA (2007) Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob Agents Chemother 51(6):1934–1938. https://doi.org/10.1128/AAC.01028-06

29. Golkar Z (2013) Experimental phage therapy on multiple drug resistant Pseudomonas aeruginosa infection in mice. J Antivirals Antimicrobials 5(06). https://doi.org/10.4172/jaa.s10-005

30. Nitz F et al (2021) Molecular detection of drug-resistance genes of bla-vpx-23-bla-xa-51 and mcr-1 in clinical isolates of pseudomonas aeruginosa. Microorganisms 9(4):1–17. https://doi.org/10.3390/microorganisms9040786
81. Rodriguez RA, Bounty S, Beck S, Chan C, McGuire C, Linden KG (2014) Photoreactivation of bacteriophages after UV disinfection: role of genome structure and impacts of UV source. Water Res 55:143–149. https://doi.org/10.1016/j.watres.2014.01.065

82. Bae KS, Shin G-A (2016) Inactivation of various bacteriophages by different ultraviolet technologies: development of a reliable virus indicator system for water reuse. Environ Eng Res 21(4):350–354. https://doi.org/10.4491/ eer.2016.032

83. Kamali E, Jamali A, Ardebili A, Ezadi F, Mohhebbi A (2020) Evaluation of antimicrobial resistance, biofilm forming potential, and the presence of biofilm-related genes among clinical isolates of Pseudomonas aeruginosa. BMC Res Notes 13(1):27. https://doi.org/10.1186/s13104-020-4890-z

84. Abedon ST, Herschler TD, Stopar D (2001) Bacteriophage latent-period evolution as a response to resource availability. Appl Environ Microbiol 67(9):4233–4241. https://doi.org/10.1128/AEM.67.9.4233-4241.2001

85. Percival SL, McCarty SM, Lipsky B (2015) Biofilms and wounds: an overview of the evidence. Adv Wound Care 4(7):373–381. https://doi.org/10.1089/wound.2014.0557

86. Adnan M et al (2020) Isolation and characterization of bacteriophage to control multidrug-resistant Pseudomonas aeruginosa planktonic cells and biofilm. Biologicals 63:89–96. https://doi.org/10.1016/j.biologicals.2019.10.003

87. Jamal M et al (2017) Isolation and characterization of bacteriophage and its utilization against multi-drug resistant Pseudomonas aeruginosa-2995. Life Sci 190:21–28. https://doi.org/10.1016/j.lfs.2017.09.034

88. Chadha P, Katere OP, Chhibber S (2016) In vivo efficacy of single phage versus phage cocktail in resolving burn wound infection in BALB/c mice. Microb Pathog 99:68–77. https://doi.org/10.1016/j.micpath.2016.08.001

89. Penziner S, Schooley RT, Pride DT (2021) Wound healing potential of topical bacteriophage therapy on diabetic cutaneous wounds. Wound Repair Regen 29(4):595–603. https://doi.org/10.1111/wrr.12056

90. Mendes JJ et al (2013) Wound healing revised: a novel reepithelialization mechanism revealed by in vitro and in silico models. J Cell Biol 203(4):691–709. https://doi.org/10.1083/jcb.2012122020

91. Basu S, Agarwal M, Kumar Bhartiya S, Nath G, Kumar Shukla V (2015) An in vivo wound model utilizing bacteriophage therapy of Pseudomonas aeruginosa biofilms. Ostomy Wound Manage 61(8):16–23 [Online]. Available: http://europepmc.org/abstract/MED/26291897

92. Kutter E, Kuhl S, Alavidze Z, Blasdel B (2012) Phage therapy: bacteriophages as natural, self-limiting antibiotics, pp 945–956

93. Safferling K et al (2013) Evaluating of the effects of sub-MIC concentrations of gentamicin on biofilm formation in clinical isolates of Pseudomonas aeruginosa. Iran J Pathol 16(4):403–410. https://doi.org/10.30699/IJP.20201.524220.2584

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.